相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions?
Terry K. W. Ma et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
ABCB1 Single-Nucleotide Polymorphisms Determine Tacrolimus Response in Patients With Ulcerative Colitis
K. R. Herrlinger et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Pharmacogenomics: Noninferiority Is Sufficient for Initial Implementation
R. B. Altman
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network
M. V. Relling et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Domperidone Treatment for Gastroparesis: Demographic and Pharmacogenetic Characterization of Clinical Efficacy and Side-Effects
Henry P. Parkman et al.
DIGESTIVE DISEASES AND SCIENCES (2011)
Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction
Jian-Ping Zhang et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2011)
Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor
Mariano A. Giorgi et al.
EXPERT OPINION ON PHARMACOTHERAPY (2011)
A Klothoβ Variant Mediates Protein Stability and Associates With Colon Transit in Irritable Bowel Syndrome With Diarrhea
Banny S. Wong et al.
GASTROENTEROLOGY (2011)
Evolving Research and Stakeholder Perspectives on Pharmacogenomics
Amber L. Beitelshees et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Genomic Medicine Genomics and Drug Response
Liewei Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome
Fei-Yuan Hsiao et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2011)
Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy
Himawan Fernando et al.
THROMBOSIS AND HAEMOSTASIS (2011)
Advances of Molecular Clinical Pharmacology in Gastroenterology and Hepatology
Joseph Prandota
AMERICAN JOURNAL OF THERAPEUTICS (2010)
Scintigraphic Biomarkers for Colonic Dysmotility
M. Camilleri
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Functional Characterization of Genetic Polymorphisms Identified in the Promoter Region of the Xanthine Oxidase Gene
Mutsumi Kudo et al.
DRUG METABOLISM AND PHARMACOKINETICS (2010)
Genetic analysis of thiopurine methyltransferase polymorphism in the Jordanian population
Nancy Hakooz et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Chenodeoxycholate in Females With Irritable Bowel Syndrome-Constipation: A Pharmacodynamic and Pharmacogenetic Analysis
Archana S. Rao et al.
GASTROENTEROLOGY (2010)
Tegaserod and the Risk of Cardiovascular Ischemic Events: An Observational Cohort Study
Jeanne Loughlin et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2010)
Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment
Guillaume Pare et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Evolution of detoxifying systems: the role of environment and population history in shaping genetic diversity at human CYP2D6 locus
Silvia Fuselli et al.
PHARMACOGENETICS AND GENOMICS (2010)
Role of genetics in prediction of disease course and response to therapy
Severine Vermeire et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2010)
Thiopurine Methyltransferase Gene Polymorphisms in Chinese Patients with Inflammatory Bowel Disease
Qian Cao et al.
DIGESTION (2009)
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group
Steven M. Teutsch et al.
GENETICS IN MEDICINE (2009)
Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis
A. C. Ford et al.
GUT (2009)
Lack of Association of Tegaserod With Adverse Cardiovascular Outcomes in a Matched Case-Control Study
Jeffrey L. Anderson et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2009)
Thiopurine S-methyltransferase (TPMT) genetic polymorphisms in Mexican newborns
A. Gonzalez-del Angel et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2009)
Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales
Johanna Sistonen et al.
PHARMACOGENETICS AND GENOMICS (2009)
Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations
Kyle J. Ellis et al.
PHARMACOGENOMICS (2009)
Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease
A. Ansari et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2008)
First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome
Johannes Kapeller et al.
HUMAN MOLECULAR GENETICS (2008)
Substrate-dependent effects of human ABCB1 coding polymorphisms
Jason M. Gow et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Functional characterization of human xanthine oxidase allelic variants
Mutsumi Kudo et al.
PHARMACOGENETICS AND GENOMICS (2008)
Ethnic variation of thiopurine S-methyltransferase activity:: a large, prospective population study
Sheldon C. Cooper et al.
PHARMACOGENOMICS (2008)
The association of serotonin transporter genetic polymorphisms and irritable bowel syndrome and its influence on tegaserod treatment in chinese patients
Yuyuan Li et al.
DIGESTIVE DISEASES AND SCIENCES (2007)
The low frequency of defective TPMT alleles in Turkish population:: A study on pediatric patients with acute lymphoblastic leukemia
Tugba Boyunegmez Tumer et al.
AMERICAN JOURNAL OF HEMATOLOGY (2007)
MDR1 polymorphisms and response to azathioprine therapy in patients with Crohn's disease
Juan L. Mendoza et al.
INFLAMMATORY BOWEL DISEASES (2007)
Alterations in expression of p11 and SERT in mucosal biopsy specimens of patients with irritable bowel syndrome
Michael Camilleri et al.
GASTROENTEROLOGY (2007)
Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine a in patients with steroid resistant ulcerative colitis
Fady Daniel et al.
INFLAMMATORY BOWEL DISEASES (2007)
Medicinal importance of grapefruit juice and its interaction with various drugs
Jawad Kiani et al.
NUTRITION JOURNAL (2007)
Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study
Edouard I. Louis et al.
PHARMACOGENETICS AND GENOMICS (2006)
Pharmacogenomics: Challenges and opportunities
Dan M. Roden et al.
ANNALS OF INTERNAL MEDICINE (2006)
Role of P-glycoprotein in statin drug interactions
Carol W. Holtzman et al.
PHARMACOTHERAPY (2006)
Clinical application of pharmacogenetics in gastrointestinal diseases
Yuri A. Saito et al.
EXPERT OPINION ON PHARMACOTHERAPY (2006)
Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: A meta analysis
PR Bakker et al.
SCHIZOPHRENIA RESEARCH (2006)
Determination of intra-ethnic differences in the polymorphisms of thiopurine S-methyltransferase in Chinese
JP Zhang et al.
CLINICA CHIMICA ACTA (2006)
The AmpliChip (TM) CYP450 Genotyping Test - Integrating a new clinical tool
Jose de Leon et al.
MOLECULAR DIAGNOSIS & THERAPY (2006)
Pharmacogenetics, drug-metabolizing enzymes, and clinical practice
Sharon J. Gardiner et al.
PHARMACOLOGICAL REVIEWS (2006)
IBD5 polymorphisms in inflammatory bowel disease: Association with response to infliximab
Elena Urcelay et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2005)
MDR1 mRNA expressions in peripheral blood mononuclear cells of patients with ulcerative colitis in relation to glucocorticoid administration
T Hirano et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Serotonin transporter: Gene, genetic disorders, and pharmacogenetics
DL Murphy et al.
MOLECULAR INTERVENTIONS (2004)
57 varieties: the human cytochromes P450
DFV Lewis
PHARMACOGENOMICS (2004)
Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease
E Louis et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease
J Winter et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori
M Schwab et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Tumour necrosis factor-α receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab
M Pierik et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
Codeine intoxication associated with ultrarapid CYP2D6 metabolism
Y Gasche et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic-polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes
DA Hesselink et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
CYPC19 polymorphism and proton pump inhibitors
U Klotz et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2004)
Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms
M Ingelman-Sundberg
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2004)
Review article: serotonin receptors and transporters - roles in normal and abnormal gastrointestinal motility
MD Gershon
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome
MD Coates et al.
GASTROENTEROLOGY (2004)
Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus
DA Hesselink et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Pharmacogenetics and clinical gastroenterology
RC Givens et al.
GASTROENTEROLOGY (2003)
CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease:: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms
LJ Egan et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism
M Kawamura et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
Pharmacogenetics of the proton pump inhibitors: A systematic review
E Chong et al.
PHARMACOTHERAPY (2003)
Drug therapy - Pharmacogenomics - Drug disposition, drug targets, and side effects
WE Evans et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Increased transcriptional activity of the CYP3A4* 1B promoter variant
B Amirimani et al.
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS (2003)
Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene:: an analysis in 534 patients from two multicenter, prospective GCP-level trials
S Mascheretti et al.
PHARMACOGENETICS (2002)
Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole
T Furuta et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease
A Ansari et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2002)
Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome
M Camilleri et al.
GASTROENTEROLOGY (2002)
A population phenotyping study of three drug-metabolizing enzymes in Kyushu, Japan, with use of the caffeine test
J Saruwatari et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
NOD2/CARD15 does not influence response to infliximab in Crohn's disease
S Vermeire et al.
GASTROENTEROLOGY (2002)
Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden
E Aklillu et al.
PHARMACOGENETICS (2002)
TNF receptor subtype signalling: Differences and cellular consequences
DJ MacEwan
CELLULAR SIGNALLING (2002)
Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses
W Urano et al.
PHARMACOGENETICS (2002)
6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease
MC Dubinsky et al.
GASTROENTEROLOGY (2002)
The genetic basis of variability in drug responses
DM Roden et al.
NATURE REVIEWS DRUG DISCOVERY (2002)
Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease
C Cuffari et al.
GUT (2001)
Molecular basis of ethnic differences in drug disposition and response
HG Xie et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2001)
Drug interactions with cisapride - Clinical implications
EL Michalets et al.
CLINICAL PHARMACOKINETICS (2000)
Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy
JF Colombel et al.
GASTROENTEROLOGY (2000)
Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease
MC Dubinsky et al.
GASTROENTEROLOGY (2000)
High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy
RJ Farrell et al.
GASTROENTEROLOGY (2000)
Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome
CM Prather et al.
GASTROENTEROLOGY (2000)
Drug-grapefruit juice interactions
GC Kane et al.
MAYO CLINIC PROCEEDINGS (2000)
分享论文
